肝疾患治療薬の世界市場レポート 2024年

肝疾患治療薬の市場規模は近年力強く成長しています。2023年の130億2,000万米ドルから2024年には140億7,000万米ドルに、CAGR8.0％で拡大します。過去の期間に見られた拡大は、肝疾患の広範な発生、アルコール消費のパターン、診断技術の進歩、肥満とメタボリックシンドロームの影響、認知度の向上、スクリーニングプログラムの実施に関連しています。さらに、肝炎の抑制を目的とした政府の取り組みも、この成長に重要な役割を果たしています。

2023年の肝疾患治療薬市場で最大の地域は北米でした。アジア太平洋は、肝疾患治療薬市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。肝疾患治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の肝疾患治療薬市場の促進要因と抑制要因
  • 促進要因
  • 抑制要因
• 実績：市場規模と成長（2018年～2023年）
• 予測：市場規模と成長（2023年～2028年、2033年）

第6章 市場セグメンテーション

• 世界の肝疾患治療薬市場：疾患タイプ別 - 実績と予測（2018年～2023年、2023年～2028年、2033年）
• 肝炎
• 非アルコール性脂肪肝疾患
• アルコール誘発性
• 肝臓がん
• 世界の肝疾患治療薬市場：治療別 - 実績と予測（2018年～2023年、2023年～2028年、2033年）
• 抗ウィルス薬
• ワクチン
• 化学療法
• 免疫抑制剤
• コルチコステロイド
• 世界の肝疾患治療薬市場：エンドユーザー別 - 実績と予測（2018年～2023年、2023年～2028年、2033年）
• 病院
• 外来手術センター
• その他

第7章 地域別および国別の分析

• 世界の肝疾患治療薬市場：地域別 - 実績と予測（2018年～2023年、2023年～2028年、2033年）
• 世界の肝疾患治療薬市場：国別 - 実績と予測（2018年～2023年、2023年～2028年、2033年）

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 競合情勢
• 企業プロファイル
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Merck &Co. Inc.
  • Novartis AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Liver Diseases Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver diseases therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
• 2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
• 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
• Companies Mentioned: Astellas Pharma Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Liver disease therapeutics encompass treatments for various liver ailments, predominantly those triggered by viruses such as hepatitis A, B, and C, often exacerbated by excessive alcohol consumption.

The primary disease classifications within liver disease therapeutics include hepatitis, non-alcoholic fatty liver disease, alcohol-induced conditions, and liver cancer. Hepatitis denotes liver inflammation caused by infectious viruses or noninfectious agents, leading to diverse health complications, some of which can be life-threatening. Treatment modalities encompass antiviral medications, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users of these therapeutics span hospitals, ambulatory surgery centers, and other sectors.

The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $13.02 billion in 2023 to $14.07 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The expansion observed in the historical period can be linked to the widespread occurrence of liver diseases, patterns of alcohol consumption, advancements in diagnostic technologies, the impact of obesity and metabolic syndrome, increased awareness, and the implementation of screening programs. Additionally, government initiatives aimed at controlling hepatitis have also played a significant role in this growth.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. Anticipated growth in the upcoming period is associated with the adoption of precision medicine strategies, advancements in RNA therapeutics, increased attention on treatments for fibrosis, the influence of patient advocacy and support groups, ongoing developments in hepatitis vaccines, and regulatory backing for orphan drugs. Key trends expected in this period encompass progress in treating hepatitis C, the emergence of innovative therapies for liver fibrosis, exploration of immunotherapies, the integration of telemedicine and remote monitoring, and a heightened focus on nutritional interventions.

The escalating incidence of liver diseases is projected to drive growth in the liver disease therapeutics market. Liver disease encompasses various conditions affecting the liver, and therapeutic interventions play a crucial role in addressing these maladies. Reports from the American Liver Foundation in September 2023 indicated a diagnosis of liver disease in 4.5 million individuals (1.8%) in the US, with 51,642 adult fatalities attributed to liver disease in 2020. Consequently, the increasing prevalence of liver diseases acts as a key driver for the expansion of the liver disease therapeutics market.

The expanding geriatric population is expected to fuel growth in the liver disease therapeutics market. Liver disease therapeutics cater to the health concerns of the elderly, significantly enhancing their quality of life and addressing liver-related conditions effectively. Global projections from the World Health Organization in October 2022 estimate that by 2030, 1 in 6 individuals globally will be aged 60 or older, reaching 2.1 billion by 2050. Additionally, data from the UK Parliament's House of Commons Library in June 2021 forecasts that by 2043, 24% of the UK's total population, approximately 17.4 million people, will comprise senior citizens. This demographic trend contributes substantially to the growth of liver disease therapeutics.

Strategic partnerships represent a prominent trend in the liver disease therapeutics market. Leading companies within this sector are engaging in collaborations to fortify their positions. For instance, in January 2022, Aligos Therapeutics Inc., a US-based biopharmaceutical company, partnered with Merck & Co. to develop oligonucleotide therapies for non-alcoholic steatohepatitis. Similarly, in January 2021, Novartis collaborated with Alnylam to develop liver-targeted therapies as potential alternatives to transplantation for patients experiencing liver failure.

Prominent players in the liver disease therapeutics market prioritize innovative technologies, notably artificial intelligence (AI), to enhance patient care. AI applications in liver disease therapeutics involve sophisticated computational algorithms and machine learning techniques to analyze medical data, facilitating early detection, precise diagnosis, and personalized treatment strategies for liver diseases. For example, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT in February 2023. hepatoSIGHT, an AI-powered tool, predicts liver fibrosis in chronic liver disease patients, aiding case-finding and cohort mapping. It offers comprehensive data analysis, machine learning algorithms, real-time risk stratification, and user-friendly interfaces for efficient patient identification within seconds.

In September 2022, GENFIT, a biopharmaceutical company headquartered in France, completed the acquisition of Versantis for an undisclosed sum. This strategic acquisition integrates Versantis' specialized expertise in liver disease therapeutics with GENFIT's extensive knowledge in executing intricate development programs focused on liver diseases. This collaboration serves to reinforce and expedite research and development efforts, substantially broadening GENFIT's pipeline in this field. Versantis, based in Switzerland, specializes in therapeutic solutions for liver diseases.

Major companies operating in the liver diseases therapeutics market report are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc

North America was the largest region in the liver diseases therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Liver Diseases Therapeutics Market Characteristics

3. Liver Diseases Therapeutics Market Trends And Strategies

4. Liver Diseases Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Liver Diseases Therapeutics Market Size and Growth

• 5.1. Global Liver Diseases Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Liver Diseases Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Liver Diseases Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Liver Diseases Therapeutics Market Segmentation

• 6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer
• 6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids
• 6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Ambulatory Surgery Centers
• Other End Users

7. Liver Diseases Therapeutics Market Regional And Country Analysis

• 7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Liver Diseases Therapeutics Market

• 8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Liver Diseases Therapeutics Market

• 9.1. China Liver Diseases Therapeutics Market Overview
• 9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Liver Diseases Therapeutics Market

• 10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Liver Diseases Therapeutics Market

• 11.1. Japan Liver Diseases Therapeutics Market Overview
• 11.2. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Liver Diseases Therapeutics Market

• 12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Liver Diseases Therapeutics Market

• 13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Liver Diseases Therapeutics Market

• 14.1. South Korea Liver Diseases Therapeutics Market Overview
• 14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Liver Diseases Therapeutics Market

• 15.1. Western Europe Liver Diseases Therapeutics Market Overview
• 15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Liver Diseases Therapeutics Market

• 16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Liver Diseases Therapeutics Market

• 17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Liver Diseases Therapeutics Market

• 18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Liver Diseases Therapeutics Market

• 19.1. Italy Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Liver Diseases Therapeutics Market

• 20.1. Spain Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Liver Diseases Therapeutics Market

• 21.1. Eastern Europe Liver Diseases Therapeutics Market Overview
• 21.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Liver Diseases Therapeutics Market

• 22.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Liver Diseases Therapeutics Market

• 23.1. North America Liver Diseases Therapeutics Market Overview
• 23.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Liver Diseases Therapeutics Market

• 24.1. USA Liver Diseases Therapeutics Market Overview
• 24.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Liver Diseases Therapeutics Market

• 25.1. Canada Liver Diseases Therapeutics Market Overview
• 25.2. Canada Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Liver Diseases Therapeutics Market

• 26.1. South America Liver Diseases Therapeutics Market Overview
• 26.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Liver Diseases Therapeutics Market

• 27.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Liver Diseases Therapeutics Market

• 28.1. Middle East Liver Diseases Therapeutics Market Overview
• 28.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Liver Diseases Therapeutics Market

• 29.1. Africa Liver Diseases Therapeutics Market Overview
• 29.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Liver Diseases Therapeutics Market Competitive Landscape
• 30.2. Liver Diseases Therapeutics Market Company Profiles
  • 30.2.1. Astellas Pharma Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bristol-Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Liver Diseases Therapeutics Market Competitive Benchmarking

32. Global Liver Diseases Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market

34. Liver Diseases Therapeutics Market Future Outlook and Potential Analysis

• 34.1 Liver Diseases Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Liver Diseases Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Liver Diseases Therapeutics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer